These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1198 related articles for article (PubMed ID: 6374238)
21. Plasminogen activators and inhibitor type-1 in alveolar osteitis. Serratì S; Margheri F; Bruschi S; D'Alessio S; Pucci M; Fibbi G; Tonelli P; Del Rosso M Eur J Oral Sci; 2006 Dec; 114(6):500-3. PubMed ID: 17184232 [TBL] [Abstract][Full Text] [Related]
22. Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastatic melanoma cells. Nip J; Rabbani SA; Shibata HR; Brodt P J Clin Invest; 1995 May; 95(5):2096-103. PubMed ID: 7537755 [TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification. Nielsen LS; Andreasen PA; Grøndahl-Hansen J; Huang JY; Kristensen P; Danø K Thromb Haemost; 1986 Apr; 55(2):206-12. PubMed ID: 3520936 [TBL] [Abstract][Full Text] [Related]
24. Spitz naevi may express components of the plasminogen activation system. Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068 [TBL] [Abstract][Full Text] [Related]
25. Immunological characterization of plasminogen activators in human mixed saliva. Kjaeldgaard A; Kjaeldgaard M Acta Physiol Scand; 1986 Mar; 126(3):443-7. PubMed ID: 3515850 [TBL] [Abstract][Full Text] [Related]
26. Content and characterization of plasminogen activators in human lung tumors and normal lung tissue. Markus G; Takita H; Camiolo SM; Corasanti JG; Evers JL; Hobika GH Cancer Res; 1980 Mar; 40(3):841-8. PubMed ID: 7193515 [TBL] [Abstract][Full Text] [Related]
27. Plasminogen activator content of human colon tumors and normal mucosae: separation of enzymes and partial purification. Corasanti JG; Celik C; Camiolo SM; Mittelman A; Evers JL; Barbasch A; Hobika GH; Markus G J Natl Cancer Inst; 1980 Aug; 65(2):345-51. PubMed ID: 6931252 [TBL] [Abstract][Full Text] [Related]
28. Secretion of plasminogen activators by human colorectal and gastric tumor explants. Harvey SR; Lawrence DD; Madeja JM; Abbey SJ; Markus G Clin Exp Metastasis; 1988; 6(6):431-50. PubMed ID: 3409559 [TBL] [Abstract][Full Text] [Related]
29. Plasminogen activators in human xenografted oro-pharyngeal squamous cell carcinomas. Björlin G; Ljungnér H; Wennerberg J; Astedt B Acta Otolaryngol; 1987; 104(5-6):568-72. PubMed ID: 3434279 [TBL] [Abstract][Full Text] [Related]
30. Expression and localization of the urokinase-type plasminogen activator receptor (uPAR) in the human placenta. Nishida Y; Hayashi Y; Imai Y; Itoh H Kobe J Med Sci; 1998 Feb; 44(1):31-43. PubMed ID: 9846056 [TBL] [Abstract][Full Text] [Related]
31. Simultaneous determination of free tissue-type and free urokinase-type plasminogen activators in biological fluids by a solid-phase immunoassay. Kuo BS; Bjornsson TD Anal Biochem; 1993 Feb; 209(1):70-8. PubMed ID: 8465964 [TBL] [Abstract][Full Text] [Related]
32. High tPA-expression in primary melanoma of the limb correlates with good prognosis. Ferrier CM; Suciu S; van Geloof WL; Straatman H; Eggermont AM; Koops HS; Kroon BB; Lejeune FJ; Kleeberg UR; van Muijen GN; Ruiter DJ Br J Cancer; 2000 Nov; 83(10):1351-9. PubMed ID: 11044361 [TBL] [Abstract][Full Text] [Related]
33. Evidence for a role of the plasminogen activator--plasmin system in corneal ulceration. Berman M; Leary R; Gage J Invest Ophthalmol Vis Sci; 1980 Oct; 19(10):1204-21. PubMed ID: 6252112 [TBL] [Abstract][Full Text] [Related]
34. Optical zymography for specific detection of urokinase plasminogen activator activity in biological samples. Law B; Hsiao JK; Bugge TH; Weissleder R; Tung CH Anal Biochem; 2005 Mar; 338(1):151-8. PubMed ID: 15707946 [TBL] [Abstract][Full Text] [Related]
35. Prognostic role of urokinase-type plasminogen activator in human gliomas. Hsu DW; Efird JT; Hedley-Whyte ET Am J Pathol; 1995 Jul; 147(1):114-23. PubMed ID: 7604873 [TBL] [Abstract][Full Text] [Related]
36. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072 [TBL] [Abstract][Full Text] [Related]
37. Effects of castration on plasminogen activator activities and plasminogen activator inhibitor type 1 in the rat ventral prostate. Wilson MJ; Ludowese C; Sinha AA; Estensen RD Prostate; 1996 Apr; 28(4):239-50. PubMed ID: 8602400 [TBL] [Abstract][Full Text] [Related]
38. In vitro plasminogen activator activity in human brain tumors. Tucker WS; Kirsch WM; Martinez-Hernandez A; Fink LM Cancer Res; 1978 Feb; 38(2):297-302. PubMed ID: 620402 [TBL] [Abstract][Full Text] [Related]
39. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. de Vries TJ; Quax PH; Denijn M; Verrijp KN; Verheijen JH; Verspaget HW; Weidle UH; Ruiter DJ; van Muijen GN Am J Pathol; 1994 Jan; 144(1):70-81. PubMed ID: 8291613 [TBL] [Abstract][Full Text] [Related]
40. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]